COVID-19 Update - This is to inform you that the Government of India has announced a complete lockdown in India 22nd March 2020 to 14th April 2020. As a result, our offices will now be closed till 14th April 2020 and all our employees will be working from home. Office telephones will not be answered, and therefore you are requested to direct all your queries related to manuscript submission, review process, publication etc. at below mentioned details. editor@innovativepublication.com, rakesh.its@gmail.com, Mob. 8826373757, 8826859373, 9910947804

Article view: 615

Article download: 221

IP Indian Journal of Immunology and Respiratory Medicine


Clinicopathological profile and treatment outcome in non-small cell lung carcinoma patients and six month survival analysis at a tertiary care center in south India


Full Text PDF Share on Facebook Share on Twitter


Author Details : Shivalinga Swamy Salimath, MD Majeed Pasha, Mohan Rao K N, Mahendra M, Sujith Halappa

Volume : 3, Issue : 2, Year : 2018

Article Page : 44-49


Suggest article by email

Abstract

Background: Lung cancer is the most common cancer and a leading cause of cancer related deaths worldwide. Non-small cell lung cancer (NSCLC) is the most common histological type. The aim of our study was to analyze clinico-pathological profile, treatment outcome and survival of NSCLC patients at a tertiary care centre.
Methodology: A total of 50 patients diagnosed histopathologically to have NSCLC were included in the study. This study was done at J.S.S Medical College and Hospital, Mysore. All patients were prospectively followed up for 6 months. Clinico-pathological profile, treatment outcome, overall survival and performance status were analyzed using Cox Proportional hazard model.
Results: Our study included a total of 50 cases with 44 male (88%) and 6 (12%) female patients with a median age of 65 years (range 42-90 years). 27 cases were adenocarcinomas (54%), 14 Squamous cell carcinomas (28%), 7 poorly differentiated carcinomas (14%) and 2 large cell carcinomas (4%).
Overall survival (OS) among patients receiving treatment was significantly better [HR=2.44(95% CI 1.14-5.22) p=0.02]. Patients treated with Chemotherapy (Carboplatin-Paclitaxel ± Gefitinib) showed significant better survival compared to patients who did not receive chemotherapy [HR=2.73(95% CI 1.03-7.25) p=0.004].
Performance status as measured by both Karnofsky score [HR=5.02(95% CI 1.51-16.67) p=0.008] and ECOG scores [HR=0.26(95% CI 0.09-0.69) p=0.006] were significantly associated with better survival in patients who took treatment.
Conclusions: NSCLC patients who took chemotherapy have a significant better survival and good quality of life.

Keywords: Chemotherapy; NSCLC; Survival.

Doi : 10.18231/2581-4222.2018.0014

How to cite : Salimath S S, Pasha M M, Mohan Rao K N, Mahendra M, Halappa S, Clinicopathological profile and treatment outcome in non-small cell lung carcinoma patients and six month survival analysis at a tertiary care center in south India. IP Indian J Immunol Respir Med 2018;3(2):44-49

Copyright © 2018 by author(s) and IP Indian J Immunol Respir Med. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (creativecommons.org)